• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

No link between TNF-a inhibitor use and cancer in inflammatory bowel disease

byJeffrey CohenandBrittany Hasty, MD
June 17, 2014
in Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this cohort study, use of TNF-a inhibitors in inflammatory bowel disease patients was not associated with an increased risk of malignancy. 

2. While a modest increased risk of malignancy was observed among those taking TNF-a inhibitors when compared to individuals who never took TNF-a inhibitors, there was no evidence of an increased risk after further controlling for azathioprine use. 

Evidence Rating Level: 2 (Good)            

Study Rundown: Inflammatory bowel disease (IBD) is often treated with tumor necrosis factor-alpha (TNF-a) inhibitors, including infliximab, adalimumab, and certolizumab pegol.  There is controversy regarding the relationship between TNF-a inhibitors and malignancy, with some trials pointing towards an increased risk of malignancy with TNF-a inhibitors use. This study included 4,553 individuals with IBD who took TNF-a inhibitors and 51,593 individuals with IBD who did not take TNF-a inhibitors and explored the association between TNF-a inhibition and malignancy. After adjusting for various factors including other medications used and disease duration, there was no increased risk of cancer among those taking TNF-a inhibitors. There was also no increased risk when specific body sites such as colorectal, skin, and hematopoietic and lymphoid tissue were examined individually.  Strengths of this study include the large number of participants and the relatively long follow up time.  Data was extracted from several databases, allowing for the most complete information possible.  There was also an allowance of a lag period before malignancy data was collected to avoid including malignancies that may have existed before exposure to TNF-a inhibition.  Weaknesses of the study include the relatively low case numbers and the inability to study individual medications separately.  Ultimately, this study argues against a relationship between TNF-a inhibitors and malignancy, but a large prospective cohort study would be helpful in exploring this question further.

Click to read the study, published today in JAMA

Relevant Reading: Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases

In-Depth [retrospective cohort]: This study explored the relationship between TNF-a inhibitors and malignancy in 4,553 individuals with IBD who took TNF-a inhibitors and 51,593 individuals with IBD who did not take TNF-a inhibitors in Denmark.  Individuals exposed to TNF-a inhibitors had a median of 3.7 years (IQR 1.8-6.0) of follow up time, received a median of 8 doses (IQR 3-17), and had a median age of 33.7 years (SD 13.9).  After adjusting for various time dependent factors and many mediations, there was a modest increased risk of malignancy among those taking TNF-a inhibitors (RR 1.25 (95% CI 1.00-1.58)).  However, after further controlling for azathioprine use, there was no increased risk of malignancy (RR 1.07 (0.85-1.36)).  This is consistent with previous data suggesting an increased risk of malignancy in individuals using azathioprine.  Further analysis was performed on specific subtypes of cancer including colorectal cancer, melanoma, and hematopoietic and lymphoid malignancies and found no increased risk of cancer in any specific site.

RELATED REPORTS

Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes

Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is associated with lower COVID-19 hospitalization and death rates compared to other treatments

Coronary microvascular dysfunction demonstrating improvement after surgery for inflammatory bowel disease

More from this author: No overall change in the prevalence of obesity in the United States between 2003 and 2012, Ambulances equipped for thrombolysis allow for more rapid stroke treatment, Physical therapy for hip osteoarthritis may not lead to significant benefits, Smaller changes in kidney filtration may predict end stage renal disease progression, Bariatric weight loss surgery linked with remission in diabetics 

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

 

Tags: IBDTNF
Previous Post

No benefit with preoperative beta-blocker use in coronary bypass surgery

Next Post

Affordable Care Act: Improved health, lower costs in youth with dependent coverage

RelatedReports

Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes

October 10, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is associated with lower COVID-19 hospitalization and death rates compared to other treatments

October 20, 2021
Addressing non-obesity related barriers may improve bariatric surgery effectiveness
Cardiology

Coronary microvascular dysfunction demonstrating improvement after surgery for inflammatory bowel disease

May 6, 2021
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Gastroenterology

Comparison of life and healthy life expectancies between IBD patients and the general population

November 16, 2020
Next Post
Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Affordable Care Act: Improved health, lower costs in youth with dependent coverage

Fibrinolysis for pulmonary embolism may prevent hemodynamic collapse [PEITHO trial]

Thrombolysis for pulmonary embolism may benefit younger patients, harm older patients

Regional central nervous damage associated with fatigue in multiple sclerosis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options